Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$575.06 USD
+2.47 (0.43%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $574.84 -0.22 (-0.04%) 4:18 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Regeneron Pharmaceuticals, Inc. has a PEG ratio of 1.30 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.63.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
REGN 575.06 +2.47(0.43%)
Will REGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
Other News for REGN
Kymera is a new Outperform at RBC Capital Markets on lead asset
REGN Crossed Above 50 Day Moving Average on September 15
J.P. Morgan Reaffirms Their Buy Rating on Regeneron (REGN)
How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse
Scholar Rock shares close 6% higher after Leerink initiates at outperform